drugset / Trial / NCT03651947

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

NCT03651947

Phase 1 Completed 168 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindPrevention

Summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Xgeva® in healthy adults.

Timeline

Start
2018-08-20
Primary completion
2018-11-17
Completion
2019-05-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody 120 mg Subcutaneous

Indications

No indication recorded.